​

Corvus Pharmaceuticals (CRVS) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

CRVS Stock Forecast

Corvus Pharmaceuticals (CRVS) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $35.00, with a high of $40.00 and a low of $30.00. This represents a 155.85% increase from the last price of $13.68.

- $8 $16 $24 $32 $40 High: $40 Avg: $35 Low: $30 Last Closed Price: $13.68

CRVS Stock Rating

Corvus Pharmaceuticals stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (92.31%), 1 Hold (7.69%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 1 12 0 Strong Sell Sell Hold Buy Strong Buy

CRVS Price Target Upside V Benchmarks

TypeNameUpside
StockCorvus Pharmaceuticals155.85%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--9
Avg Price Target--$27.56
Last Closing Price$13.68$13.68$13.68
Upside/Downside--101.46%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2616---7
Jun, 2616---7
May, 2616---7
Apr, 2616---7
Mar, 2616---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 17, 2026Goldman Sachs$40.00$15.04165.96%192.40%
Jan 29, 2026Graig SuvannavejhMizuho Securities$30.00$20.5446.06%119.30%
Jan 22, 2026Roger SongJefferies$42.00$25.8062.79%207.02%
Jan 21, 2026Oppenheimer$32.00$22.5441.97%133.92%
Jan 20, 2026Barclays$28.00$21.4130.78%104.68%
Jan 20, 2026Mizuho Securities$20.00$19.522.46%46.20%
Jan 20, 2026Sean LeeH.C. Wainwright$27.00$18.2248.19%97.37%
Oct 29, 2025Mizuho Securities$13.00$7.5572.19%-4.97%
Oct 13, 2025Barclays$16.00$6.93130.88%16.96%
May 20, 2025Graig SuvannavejhMizuho Securities$11.00$3.68198.91%-19.59%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 17, 2026Goldman SachsBuyinitialise
Mar 13, 2026Cantor FitzgeraldOverweightOverweighthold
Jan 22, 2026JefferiesBuyBuyhold
Jan 21, 2026OppenheimerOutperformOutperformhold
Jan 20, 2026BarclaysOverweightOverweighthold
Jan 20, 2026H.C. WainwrightBuyBuyhold
Dec 11, 2025Cantor FitzgeraldOverweightOverweighthold
Oct 13, 2025BarclaysOverweightinitialise
Mar 26, 2025OppenheimerOutperformOutperformhold
Jan 02, 2025H.C. WainwrightBuyinitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.56$-1.02$-0.19---
Avg Forecast$-0.55$-0.92$-0.47$-0.60$-0.50$-0.07
High Forecast$-0.54$-0.90$-0.42$-0.41$-0.28$-0.07
Low Forecast$-0.56$-0.95$-0.53$-0.80$-0.78$-0.07
Surprise %1.82%10.87%-59.57%---

Revenue Forecast

$0 $15M $30M $45M $60M $75M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$775.00K$4.37M$23.23M$70.57M
High Forecast--$775.00K$4.37M$23.23M$70.57M
Low Forecast--$775.00K$4.37M$23.23M$70.57M
Surprise %------

Net Income Forecast

$-65M $-52M $-39M $-26M $-13M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-27.03M$-62.29M$-15.28M---
Avg Forecast$-26.29M$-44.50M$-22.79M$-29.06M$-25.28M$-3.24M
High Forecast$-25.82M$-43.30M$-20.05M$-19.69M$-13.28M$-3.24M
Low Forecast$-26.76M$-45.71M$-25.52M$-38.42M$-37.27M$-3.24M
Surprise %2.80%39.97%-32.93%---

CRVS Forecast FAQ

Is Corvus Pharmaceuticals stock a buy?

Corvus Pharmaceuticals stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Corvus Pharmaceuticals is a favorable investment for most analysts.

What is Corvus Pharmaceuticals's price target?

Corvus Pharmaceuticals's price target, set by 13 Wall Street analysts, averages $35 over the next 12 months. The price target range spans from $30 at the low end to $40 at the high end, suggesting a potential 155.85% change from the previous closing price of $13.68.

How does Corvus Pharmaceuticals stock forecast compare to its benchmarks?

Corvus Pharmaceuticals's stock forecast shows a 155.85% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Corvus Pharmaceuticals over the past three months?

  • July 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Corvus Pharmaceuticals’s EPS forecast?

Corvus Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.6, marking a 215.79% increase from the reported $-0.19 in 2025. Estimates for the following years are $-0.5 in 2027, and $-0.07 in 2028.

What is Corvus Pharmaceuticals’s revenue forecast?

Corvus Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $4.37M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $23.23M, and $70.57M for 2028.

What is Corvus Pharmaceuticals’s net income forecast?

Corvus Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-29.055M, representing an 90.12% increase from the reported $-15.283M in 2025. Projections indicate $-25.276M in 2027, and $-3.242M in 2028.